Details of the Drug Reposition

General Information of This Drug (ID: DM2S26S)

Drug Name
Pegaspargase   DM2S26S
Synonyms Oncaspar (TN)

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Childhood acute lymphoblastic leukemia DISJ5D6U N.A. Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphocytic leukaemia DISPX75S 2B33.3 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505.
2 Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 Jul 1;40(19):2106-2118.
3 High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment